Business
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PAD, 42% uORR at 24-32 mg QD RDE, and 50% uORR at 32 mg QD Monotherapy generally well-tolerated with mostly low-grade AEs, no DLTs as of DCO, and low rate of dose reductions and no discontinuations due to TRAEs Preliminary data suggest ERAS-0015 may combine safely
About this update from Erasca, Inc.
[{"type":"image","alt":"Erasca, Inc.","displaySize":"","headline":null,"caption":"Erasca, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":49,"url":"https://media.zenfs.com/en/globenewswire.com/0b48dd84fa0cc496a6fda02f84d9b85c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sKuLSdAV0vQhEZPku0Kxnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY5/https://media.zenfs.com/en/globenewswire.com/0b48dd84fa0cc496a6fda02f84d9b85c","width":300,"height":49}},"lazy":false},{"type":"text","content":"Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE","length":161,"tagName":"p"},{"type":"text","content":"Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PAD, 42% uORR at 24-32 mg QD RDE, and 50% uORR at 32 mg QD","length":132,"tagName":"p"},{"type":"text","content":"Monotherapy generally well-tolerated with mostly low-grade AEs, no DLTs as of DCO, and low rate of dose reductions and no discontinuations due to TRAEs","length":151,"tagName":"p"},{"type":"text","content":"Preliminary data suggest ERAS-0015 may combine safely with standard-of-care doses of panitumumab with no DLTs as of DCO (N=3) and 1/1 uPR in CRC","length":144,"tagName":"p"},{"type":"text","content":"Well-behaved PK, with dose-dependent increase in PK exposure up to MAD of 40 mg QD and no exposure plateau observed","length":115,"tagName":"p"},{"type":"text","content":"Anticipated data disclosure of select ERAS-0015 monotherapy dose expansion and combination dose escalation cohorts narrowed to H1 2027","length":134,"tagName":"p"},{"type":"text","content":"Conference call and live webcast today at 4:30 PM Eastern Time","length":62,"tagName":"p"},{"type":"text","content":"SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced positive preliminary Phase 1 dose escalation data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.","length":422,"tagName":"p"},{"type":"text","content":"The preliminary data are from Erasca’s ongoing AURORAS-1 Phase 1 dose escalation trial in the U.S. a...